Janney Capital Upgrades DepoMed Inc (DEPO) to Buy

Go back to Janney Capital Upgrades DepoMed Inc (DEPO) to Buy

DepoMed (DEPO) Sell-Off an 'Over-Reaction', Roth Capital Says; PT to $28.50

May 12, 2015 12:42 PM EDT

Roth Capital analyst Scott Henry trimmed his price target on DepoMed Inc (NASDAQ: DEPO) to $28.50 (from $30.00) following Q1 results but maintained a Buy rating. The firm views today's 18% sell-off as a "over-reaction."

Henry commented, "DEPO reported 1Q15 results that were at the lower end... More